Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Incannex Healthcare Ltd ADR (IXHL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/14/2025: IXHL (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
0 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
Analysis of Past Performance
Type Stock | Historic Profit -65.36% | Avg. Invested days 17 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 19.05M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 2.47 | 52 Weeks Range 0.08 - 3.12 | Updated Date 06/29/2025 |
52 Weeks Range 0.08 - 3.12 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.23 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -20952.04% |
Management Effectiveness
Return on Assets (TTM) -76.74% | Return on Equity (TTM) -201.88% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 14183550 | Price to Sales(TTM) 194.37 |
Enterprise Value 14183550 | Price to Sales(TTM) 194.37 | ||
Enterprise Value to Revenue 144.73 | Enterprise Value to EBITDA -5.13 | Shares Outstanding 93695400 | Shares Floating 28234076 |
Shares Outstanding 93695400 | Shares Floating 28234076 | ||
Percent Insiders 26.14 | Percent Institutions 8.29 |
Upturn AI SWOT
Incannex Healthcare Ltd ADR
Company Overview
History and Background
Incannex Healthcare Ltd is a pharmaceutical company focused on developing unique medicinal cannabis pharmaceutical products and psychedelic medicine therapies for unmet medical needs. Founded in 2015, the company has focused on developing patented drug delivery systems and novel therapies.
Core Business Areas
- Medicinal Cannabis Pharmaceuticals: Development of proprietary medicinal cannabis products using advanced drug delivery systems for conditions like obstructive sleep apnea, anxiety, and pain.
- Psychedelic Medicine Therapies: Research and development of psychedelic-assisted psychotherapy treatments for conditions such as generalized anxiety disorder and traumatic brain injury. Utilizes compounds like psilocybin.
Leadership and Structure
The company's leadership team includes a board of directors and executive management focused on pharmaceutical development, clinical trials, and regulatory approvals. The structure involves research and development, clinical operations, and commercial strategy departments.
Top Products and Market Share
Key Offerings
- IHL-42X (Obstructive Sleep Apnea): A proprietary cannabinoid formulation for the treatment of obstructive sleep apnea. Currently in Phase 2 trials. Competitors include traditional CPAP therapy and surgical interventions. Market share data unavailable as the product is not yet commercially available.
- Psilocybin-Assisted Psychotherapy (Generalized Anxiety Disorder): Investigating psilocybin-assisted psychotherapy for generalized anxiety disorder. Currently in Phase 2 trials. Competitors include traditional psychotherapy and antidepressant medications. Market share data unavailable as the product is not yet commercially available.
Market Dynamics
Industry Overview
The medicinal cannabis and psychedelic medicine industries are experiencing rapid growth, driven by increasing acceptance of alternative therapies and evolving regulations. The market is characterized by significant investment in research and development and increasing focus on FDA-approved pharmaceutical products.
Positioning
Incannex is positioned as a developer of proprietary pharmaceutical-grade cannabinoid and psychedelic medicine therapies, differentiating itself through patented delivery systems and rigorous clinical trials. It aims to provide evidence-based alternative treatments for unmet medical needs.
Total Addressable Market (TAM)
The total addressable market for obstructive sleep apnea and mental health disorders is significant, estimated to be in the billions of dollars globally. Incannex's position depends on successful clinical trials and regulatory approvals, placing it to capture a share of this TAM in the future.
Upturn SWOT Analysis
Strengths
- Proprietary drug delivery systems
- Focus on FDA-approved pharmaceutical products
- Diverse pipeline of cannabinoid and psychedelic medicine therapies
- Experienced management team
Weaknesses
- Reliance on successful clinical trial outcomes
- Dependence on regulatory approvals
- Limited revenue generation prior to product launch
- High cash burn rate
Opportunities
- Expanding market for medicinal cannabis and psychedelic medicine
- Potential for strategic partnerships with pharmaceutical companies
- Growing acceptance of alternative therapies
- Advancements in drug delivery technology
Threats
- Regulatory hurdles and evolving regulations
- Competition from established pharmaceutical companies
- Clinical trial failures
- Negative public perception of cannabis and psychedelics
Competitors and Market Share
Key Competitors
- GWPH
- CRBP
- ALZN
- NUMI
Competitive Landscape
Incannex's advantage lies in its novel drug delivery systems and dual focus on cannabinoid and psychedelic medicines. Disadvantages include the need to navigate regulatory hurdles and compete with larger, more established pharmaceutical companies. Note: Since the company is not selling any commercialized product, it would be premature to suggest any Market Share numbers.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is tied to the progression of their clinical programs and successful capital raises. Recent periods have been marked by increased R&D spending and clinical trial activity.
Future Projections: Future growth depends on successful clinical trial outcomes, regulatory approvals, and commercialization of their products. Analyst estimates would be required for specific projections.
Recent Initiatives: Recent initiatives include advancing clinical trials for IHL-42X and psychedelic therapies, securing patents for drug delivery systems, and exploring strategic partnerships.
Summary
Incannex Healthcare is a pharmaceutical company with a focus on cannabinoid and psychedelic medicine. The company's strengths lie in its proprietary drug delivery systems and diverse pipeline, but it faces challenges in navigating regulatory hurdles and securing clinical trial success. The company's future success depends on favorable clinical trial outcomes and successful commercialization. Incannex's financial health is contingent upon strategic partnerships and funding to continue its research and development activities.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports (where available)
- Industry News
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. The data provided is based on available public information and may not be entirely accurate or complete. Investments in pharmaceutical companies are inherently risky, and investors should consult with a financial professional before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Incannex Healthcare Ltd ADR
Exchange NASDAQ | Headquaters Sydney, NSW, Australia | ||
IPO Launch date 2022-03-02 | President, CEO & Executive Director Mr. Joel Bradley Latham | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 9 | Website https://www.incannex.com |
Full time employees 9 | Website https://www.incannex.com | ||
Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research, development, manufacture, sale, and distribution of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that has completed Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety disorder. It is also developing IHL-675A, an oral fixed dose combination drug containing synthetic cannabidiol and hydroxychloroquine sulphate in Phase 2 clinical trial to treat rheumatoid arthritis, as well as lung inflammation, acute respiratory disease, chronic obstructive pulmonary disease, asthma, bronchitis, inflammatory bowel disease, colitis, and Crohn's disease. Incannex Healthcare Inc. is headquartered in Sydney, Australia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.